meglumine antimoniate has been researched along with Abnormalities, Drug-Induced in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bamorovat, M; Derakhshanfar, A; Keyhani, AR; Khosravi, A; Mosallanejad, SS; Salari, Z; Sharifi, I; Tavakkoli, H | 1 |
| De-Carvalho, RR; Miekeley, N; Miranda, ES; Paumgartten, FJ | 1 |
2 other study(ies) available for meglumine antimoniate and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model.
Topics: Abnormalities, Drug-Induced; Animals; Antiprotozoal Agents; Avian Proteins; Blood Vessels; Chick Embryo; Drug Evaluation, Preclinical; Female; Gene Expression; Meglumine; Meglumine Antimoniate; Models, Animal; Neovascularization, Physiologic; Organometallic Compounds; RNA, Messenger; Teratogens; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat.
Topics: Abnormalities, Drug-Induced; Animals; Antimony; Antiprotozoal Agents; Bone and Bones; Dose-Response Relationship, Drug; Female; Fetal Blood; Fetal Death; Fetal Development; Fetal Weight; Maternal-Fetal Exchange; Meglumine; Meglumine Antimoniate; No-Observed-Adverse-Effect Level; Organometallic Compounds; Placenta; Pregnancy; Rats; Rats, Wistar | 2006 |